Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer
Status:
Completed
Trial end date:
2019-01-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether AZD1775 has any effect on the
pharmacokinetics (PK) of three compounds (caffeine, omeprazole, and midazolam) that are
probes for common drug-metabolizing enzymes (caffeine-CYP1A2, omeprazole-CYP2C19,
midazolam-CYP3A). The study also seeks to determine the effect of AZD1775 on the QTc
interval, which is a common measure of cardiac (heart) function.